Kidney Week

Abstract: SA-PO048

SGLT2 Inhibitor Treatment during AKI and Its Association with Major Adverse Kidney Events

Session Information

• AKI: Clinical, Outcomes, and Trials - Management
  October 26, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

• 102 AKI: Clinical, Outcomes, and Trials

Authors

• Chavez, Jonathan, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

Jonathan Chavez, PhD

• Garcia-Garcia, Guillermo, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

Guillermo Garcia-Garcia, MD, FASN

• Medina, Ramon, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

Ramon Medina, MD

• Ruiz Ochoa, Francisco Octavio, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

Francisco Octavio Ruiz Ochoa

• Navarro Viramontes, Yulene, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

Yulene Navarro Viramontes

• Ramírez, Narda Carolina, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

Narda Carolina Ramírez, APN, APRN, CAE

• De la Rosa Medina, Jose Guillermo, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

Jose Guillermo De la Rosa Medina, MD

• De la Torre De la Vega, Ixchel, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

Ixchel De la Torre De la Vega, MD

• Langarica López, Jenifer Monserrat, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

Jenifer Monserrat Langarica López

• Cruz Aragon, Fernando, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

Fernando Cruz Aragon, MD

• Navarro Blackaller, Guillermo, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

Guillermo Navarro Blackaller, MD

• Alcantar Vallin, Maria de la Luz, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

Maria de la Luz Alcantar Vallin, MD

Background

The association between the administration of sodium–glucose cotransporter 2 inhibitors (SGLT2i) during acute kidney injury (AKI) and the incidence of major adverse kidney events (MAKEs) is not known.

Methods

This retrospective cohort study included patients with AKI and compared outcomes for those who were treated with SGLT2i during hospitalization and those without SGLT2i treatment. The associations of SGLT2i use with MAKEs at 10 and 30-90 days, each individual MAKE component and the prespecified patient subgroups were analyzed.

Results

From 2021 to 2023, 374 patients were included—316 without SGLT2i use and 58 with SGLT2i use. Patients who were treated with SGLT2i were older; had a greater prevalence of diabetes, hypertension, chronic heart failure and chronic kidney disease; required hemodialysis less often; and presented stage 3 AKI less frequently than those who were not treated with SGLT2i. Logistic regression analysis with nearest-neighbor matching revealed that SGLT2i use was not associated with the risk of MAKE10 (OR 1.08 [0.45-2.56]) or with MAKE30-90 (OR 0.76 [0.42-1.36]). For death, the stepwise approach demonstrated that SGLT2i use was associated with a reduced risk (OR 0.08; 0.01-0.64), and no effect was found for kidney replacement therapy (KRT). The subgroups of patients who experienced a reduction in the risk of MAKE in patients with AKI treated with SGLT2i were those older than 61 years, those with an eGFR >81, and those without a history of hypertension or DM (p ≤0.05 for all).

Conclusion

The use of SGLT2i during AKI had no effect on short- or medium-term MAKE, but some subgroups of patients may have experienced benefits from SGLT2i treatment.